HFE

Chr 6AR

homeostatic iron regulator

Also known as: HFE1, HH, HLA-H, MVCD7, TFQTL2

The protein encoded by this gene is a membrane protein that is similar to MHC class I-type proteins and associates with beta2-microglobulin (beta2M). It is thought that this protein functions to regulate iron absorption by regulating the interaction of the transferrin receptor with transferrin. The iron storage disorder, hereditary haemochromatosis, is a recessive genetic disorder that results from defects in this gene. [provided by RefSeq, May 2022]

Primary Disease Associations & Inheritance

Hemochromatosis, type 1MIM #235200
AR
UniProtHemochromatosis 1
349
ClinVar variants
52
Pathogenic / LP
0.00
pLI score
12
Active trials
Clinical SummaryHFE
🧬
Gene-Disease Validity (ClinGen)
hemochromatosis type 1 · ARDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
52 Pathogenic / Likely Pathogenic· 132 VUS of 349 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
1.19LOEUF
pLI 0.000
Z-score 0.96
OE 0.76 (0.501.19)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
0.63Z-score
OE missense 0.87 (0.770.99)
165 obs / 189.5 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.76 (0.501.19)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.87 (0.770.99)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.0.89
01.21.6
LoF obs/exp: 14 / 18.5Missense obs/exp: 165 / 189.5Syn Z: 0.76

ClinVar Variant Classifications

349 submitted variants in ClinVar

Classification Summary

Pathogenic32
Likely Pathogenic20
VUS132
Likely Benign140
Benign10
Conflicting15
32
Pathogenic
20
Likely Pathogenic
132
VUS
140
Likely Benign
10
Benign
15
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
10
1
21
0
32
Likely Pathogenic
13
3
4
0
20
VUS
5
88
38
1
132
Likely Benign
0
1
43
96
140
Benign
0
0
9
1
10
Conflicting
15
Total289311598349

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

HFE · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Gene2Phenotype Curations

HFE-related haemochromatosis

definitive
ARLoss Of FunctionAbsent Gene Product
Skin
G2P ↗

Gene2Phenotype curations · DECIPHER consortium patient cohort (public variants) · deciphergenomics.org

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

Hemochromatosis, type 1

MIM #235200

Molecular basis of disorder known

Autosomal recessive
📖
GeneReview available — HFE
Authoritative clinical overview · NCBI Bookshelf · Recommended first read
Open GeneReview ↗
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
Haemochromatosis.
Brissot P et al.·Nat Rev Dis Primers
2018Review
Hereditary haemochromatosis: A review.
Singh P et al.·J R Coll Physicians Edinb
2024Review
Iron and the liver.
Pietrangelo A·Liver Int
2016Review
Hereditary hemochromatosis.
Pietrangelo A·Biochim Biophys Acta
2006Review
Non-HFE hemochromatosis.
Pietrangelo A·Semin Liver Dis
2005Review
Diabetes in HFE Hemochromatosis.
Barton JC et al.·J Diabetes Res
2017Review
Juvenile haemochromatosis.
Camaschella C·Baillieres Clin Gastroenterol
1998Review
Non-HFE haemochromatosis.
Wallace DF et al.·World J Gastroenterol
2007Review
Top 10 resultsSearch PubMed ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET AmplificationLung Adenocarcinoma Stage IIIB/IV

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

ACTIVE NOT RECRUITING
NCT02864992Phase PHASE2EMD Serono Research & Development Institute, Inc.Started 2016-09-13
Tepotinib
Myocardial Infarction (MI)

Efficacy of Montelukast on STEMl Patients

RECRUITING
NCT07320625Phase PHASE3Shanghai Zhongshan HospitalStarted 2026-02-01
MontelukastPlacebo
Fabry Disease

T1 Mapping in Fabry Disease

RECRUITING
NCT05923788Phase NAHospices Civils de LyonStarted 2023-08-07
T1 mapping measurement
TNBC, Triple Negative Breast Cancer

Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)

RECRUITING
NCT06682195Phase PHASE2First Affiliated Hospital of Zhejiang UniversityStarted 2024-10-09
Neoadjuvant chemotherapy combined with Toripalimab
Leukemia, Myeloid, Acute

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

RECRUITING
NCT06852222Phase PHASE3Janssen Research & Development, LLCStarted 2025-06-04
BleximenibVenetoclax (VEN)Azacitidine (AZA)
Acute Coronary Syndrome

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

ACTIVE NOT RECRUITING
NCT05754957Phase PHASE3Janssen Research & Development, LLCStarted 2023-04-07
MilvexianPlacebo
NSCLC (Advanced Non-small Cell Lung Cancer)

QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC

RECRUITING
NCT07330596Phase PHASE2Anhui Provincial Cancer HospitalStarted 2025-10-30
QL1706 combined with ChemotherapyChemotherapy
Neovascular Age-related Macular Degeneration

Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)

RECRUITING
NCT05986864Phase PHASE1, PHASE2Skyline Therapeutics (US) Inc.Started 2024-02-23
SKG0106
AML, ChildhoodAcute Myeloid Leukemia

Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML

RECRUITING
NCT06221683Phase PHASE2Children's Hospital of Soochow UniversityStarted 2024-01-01
HomoharringtonineCytarabineEtoposide
Asymptomatic Intracranial StenosisCognitive ImpairmentCerebrovascular Event

Cognitive Decline and Underlying Mechanisms in Asymptomatic Intracranial Artery Stenosis Patients

RECRUITING
NCT05504330Anhui Medical UniversityStarted 2022-08-15
Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin
Chronic Obstructive Pulmonary Disease COPD

A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

RECRUITING
NCT07292714Phase PHASE2Mabwell (Shanghai) Bioscience Co., Ltd.Started 2025-07-15
9MW1911Phase II placebo
Neovascular Age-Related Macular Degeneration

Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)

ACTIVE NOT RECRUITING
NCT06196840Phase PHASE2Innostellar Biotherapeutics Co.,LtdStarted 2024-01-24
LX102 subretinal injectionAflibercept intravitreal injection